4 stories this morning, for surgeons and the people who support them.
- Bioventus Q3 2026: revenue $142.4M (+2.7%); Pain Treatments +6.2% on Durolane, PRP and PNS; Surgical Solutions +0.7% (U.S. -2.8%) on softer bone graft substitutes; Restorative Therapies -3.4% on EXOGEN; FY26 net sales guidance cut to $590-595M from $600-610M; adjusted EPS $0.75-0.79 reaffirmed; strategic alternatives review (opened Aug 5 after an unsolicited proposal) continues — Bioventus reported Q3 results on November 2 and lowered full-year sales guidance to $590-595M (4-5% growth) from $600-610M (6-7%), while its board's review of strategic alternatives, including a possible sale, continues with no timetable. Source
- Highridge Medical, the former ZimVie spine business owned by H.I.G. Capital, names Rob Fredericks CEO (ex-Lighteum Medical, Merit Medical, C.R. Bard; spine experience at Medtronic); Eric Major remains executive chairman — On November 2 Highridge named Rob Fredericks chief executive, filling the post Rebecca Whitney said in June she was leaving; Highridge carries Mobi-C, the activL lumbar disc (limited launch Feb 2026) and The Tether (UnitedHealthcare coverage April 2026). Source
- Bone Joint J, Norwegian Arthroplasty and Hip Fracture Registers: in 204,041 primary hip arthroplasties (2005-2025), reoperation for periprosthetic femoral fracture in men was ~9x higher with polished taper-slip and uncemented collarless stems and ~4x with uncemented collared stems vs cemented composite-beam stems; age thresholds for excess risk differed by sex and design — Registry analysis concluding composite-beam stems should be preferred at least in men over 75 and women over 70, with collared stems the best uncemented option and taper-slip stems high-risk in men at all ages. Source
- J Arthroplasty double-blind RCT, 86 primary TKA patients: extended oral tranexamic acid (1.95 g/day POD 1-3) after standard IV TXA did not improve VAS pain at any point to 12 weeks, ROM, opioid use or ambulation vs placebo — Connecticut Joint Replacement Institute trial found no benefit from extended oral TXA after primary TKA; authors say broad use of the protocol may not be warranted. Source
Contribute to the Brief
Faculty can send the show a note — a reaction to a paper, a correction, a read on a rule change — either written, which we shape for broadcast and read in the show's voice, or as a voice note under three minutes, which airs in your own voice. Send one from Studio.
Not on doc social yet? Contribute a lecture or join the network — doc social is a clinical education platform for clinicians, and this show is one part of it.
Narration is synthesized. Reporting and editorial judgement are ours, and every story above links to its source.